Cargando…
The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study
There is a close relationship between inflammatory cells and tumors, but the pathways that connect the two remain unclear. This research explores the clinical and prognostic value of the systemic inflammation response index (SIRI) in breast cancer patients. The study included 477 breast cancer patie...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918696/ https://www.ncbi.nlm.nih.gov/pubmed/35295846 http://dx.doi.org/10.3389/fmolb.2022.856064 |
_version_ | 1784668787637747712 |
---|---|
author | Zhu, Mengliu Chen, Li Kong, Xiangyi Wang, Xiangyu Fang, Yi Li, Xingrui Wang, Jing |
author_facet | Zhu, Mengliu Chen, Li Kong, Xiangyi Wang, Xiangyu Fang, Yi Li, Xingrui Wang, Jing |
author_sort | Zhu, Mengliu |
collection | PubMed |
description | There is a close relationship between inflammatory cells and tumors, but the pathways that connect the two remain unclear. This research explores the clinical and prognostic value of the systemic inflammation response index (SIRI) in breast cancer patients. The study included 477 breast cancer patients who underwent neoadjuvant chemotherapy and 308 breast cancer patients who did not in our center between January 1998 and December 2016. Optimal SIRI threshold values were determined using the receiver operating characteristic curve (ROC). Patients were then reclassified as SIRI ≥0.80 group (High SIRI group) and SIRI <0.80 group (Low SIRI group). The outcomes were analyzed by statistical methods. The univariate and multivariate analyses demonstrated that SIRI independently predicted survival in breast cancer. The disease-free survival (DFS) and overall survival (OS) in patients with low SIRI scores were significantly longer in contrast to those with high SIRI scores (41.50 vs. 37.63 months, and 64.57 vs. 58.42 months). Further subgroup analyses revealed that low SIRI score patients who also had either early breast cancer, advanced breast cancer, or different molecular subtypes also possessed longer mean survival time of DFS and OS in contrast to those with high SIRI levels (χ2 = 2.379, p = 0.123, and χ2 = 5.153, p = 0.023; χ2 = 11.080, p = 0.0009 and χ2 = 15.900, p < 0.0001; χ2 = 16.020, p < 0.0001 and χ2 = 22.050, p < 0.0001, respectively). SIRI serves as an easily accessible, replicable, and minimally invasive prognostic tool in breast cancer patients. Lower SIRI scores were predictive of a longer DFS and OS after surgery in breast cancer patients. SIRI may serve as a marker to guide clinical management and prognostication of breast cancer. |
format | Online Article Text |
id | pubmed-8918696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89186962022-03-15 The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study Zhu, Mengliu Chen, Li Kong, Xiangyi Wang, Xiangyu Fang, Yi Li, Xingrui Wang, Jing Front Mol Biosci Molecular Biosciences There is a close relationship between inflammatory cells and tumors, but the pathways that connect the two remain unclear. This research explores the clinical and prognostic value of the systemic inflammation response index (SIRI) in breast cancer patients. The study included 477 breast cancer patients who underwent neoadjuvant chemotherapy and 308 breast cancer patients who did not in our center between January 1998 and December 2016. Optimal SIRI threshold values were determined using the receiver operating characteristic curve (ROC). Patients were then reclassified as SIRI ≥0.80 group (High SIRI group) and SIRI <0.80 group (Low SIRI group). The outcomes were analyzed by statistical methods. The univariate and multivariate analyses demonstrated that SIRI independently predicted survival in breast cancer. The disease-free survival (DFS) and overall survival (OS) in patients with low SIRI scores were significantly longer in contrast to those with high SIRI scores (41.50 vs. 37.63 months, and 64.57 vs. 58.42 months). Further subgroup analyses revealed that low SIRI score patients who also had either early breast cancer, advanced breast cancer, or different molecular subtypes also possessed longer mean survival time of DFS and OS in contrast to those with high SIRI levels (χ2 = 2.379, p = 0.123, and χ2 = 5.153, p = 0.023; χ2 = 11.080, p = 0.0009 and χ2 = 15.900, p < 0.0001; χ2 = 16.020, p < 0.0001 and χ2 = 22.050, p < 0.0001, respectively). SIRI serves as an easily accessible, replicable, and minimally invasive prognostic tool in breast cancer patients. Lower SIRI scores were predictive of a longer DFS and OS after surgery in breast cancer patients. SIRI may serve as a marker to guide clinical management and prognostication of breast cancer. Frontiers Media S.A. 2022-02-28 /pmc/articles/PMC8918696/ /pubmed/35295846 http://dx.doi.org/10.3389/fmolb.2022.856064 Text en Copyright © 2022 Zhu, Chen, Kong, Wang, Fang, Li and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Zhu, Mengliu Chen, Li Kong, Xiangyi Wang, Xiangyu Fang, Yi Li, Xingrui Wang, Jing The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study |
title | The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study |
title_full | The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study |
title_fullStr | The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study |
title_full_unstemmed | The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study |
title_short | The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study |
title_sort | systemic inflammation response index as an independent predictor of survival in breast cancer patients: a retrospective study |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918696/ https://www.ncbi.nlm.nih.gov/pubmed/35295846 http://dx.doi.org/10.3389/fmolb.2022.856064 |
work_keys_str_mv | AT zhumengliu thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT chenli thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT kongxiangyi thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT wangxiangyu thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT fangyi thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT lixingrui thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT wangjing thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT zhumengliu systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT chenli systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT kongxiangyi systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT wangxiangyu systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT fangyi systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT lixingrui systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy AT wangjing systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy |